BACKGROUND AND OBJECTIVE: We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). METHODS: Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV1) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and absence of major extrapulmonary comorbidities. The study consisted of 2 phases; in phase 1, the criteria for inclusion in RCTs on COPD were selected, and in phase 2, the above criteria were applied to an unselected outpatient COPD population. RESULTS: A total of 578 subjects (83% of the whole group) failed at least one of the inclusion criteria. Lung diseases other than COPD (occurring in 30% of our population, mostly bronchiectasis), long-term oxygen therapy (31%), FEV1 (19%), age (14%) and extrapulmonary comorbidities such as cognitive impairment (14%), arrhythmias (17%) and congestive heart disease (13%) would have been the most frequent causes for exclusion from RCTs. CONCLUSIONS: In real-life settings, more than 80% of COPD subjects are currently treated by protocols based on results of RCTs for which they would not have been eligible. We encourage a more extensive use of pragmatic trials in COPD to better modulate the application of results of RCTs to patients encountered in daily practice.
BACKGROUND AND OBJECTIVE: We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). METHODS: Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV1) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and absence of major extrapulmonary comorbidities. The study consisted of 2 phases; in phase 1, the criteria for inclusion in RCTs on COPD were selected, and in phase 2, the above criteria were applied to an unselected outpatientCOPD population. RESULTS: A total of 578 subjects (83% of the whole group) failed at least one of the inclusion criteria. Lung diseases other than COPD (occurring in 30% of our population, mostly bronchiectasis), long-term oxygen therapy (31%), FEV1 (19%), age (14%) and extrapulmonary comorbidities such as cognitive impairment (14%), arrhythmias (17%) and congestive heart disease (13%) would have been the most frequent causes for exclusion from RCTs. CONCLUSIONS: In real-life settings, more than 80% of COPD subjects are currently treated by protocols based on results of RCTs for which they would not have been eligible. We encourage a more extensive use of pragmatic trials in COPD to better modulate the application of results of RCTs to patients encountered in daily practice.
Authors: Òscar Miró; Víctor Gil; Christian Müller; Alexander Mebazaa; Héctor Bueno; Francisco Javier Martín-Sánchez; Pablo Herrero; Javier Jacob; Pere Llorens Journal: Clin Res Cardiol Date: 2015-04-24 Impact factor: 5.460
Authors: Rebecca N Jerome; Terri L Edwards; Haley C Boswell; Gordon R Bernard; Paul A Harris; Jill M Pulley Journal: Acad Med Date: 2016-03 Impact factor: 6.893
Authors: Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber Journal: Br J Clin Pharmacol Date: 2015-12-23 Impact factor: 4.335
Authors: Peter Kardos; Sally Worsley; Dave Singh; Miguel Román-Rodríguez; David E Newby; Hana Müllerová Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-11-25
Authors: David B Price; Eran Gefen; Gokul Gopalan; Rosie McDonald; Vicky Thomas; Simon Wan Yau Ming; Emily Davis Journal: PLoS One Date: 2018-01-24 Impact factor: 3.240